Compare Cytokinetics Inc (CYTK) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Cytokinetics Inc trades at $62.77 (market cap $8.62B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.18 (market cap $560.32M). The key difference: Cytokinetics Inc is far larger — about 15.4× Direxion Daily FTSE China Bull 3x Shares's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| CYTK | YINN | |
|---|---|---|
Market Cap | $8.62B | $560.32M |
Volume | 2,594,626 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $87.26 | $52.69 |
52-Week Low | $54.76 | $21.45 |
Typical Hold Time | 19 Days | 25 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
YINN is trading at $25.09, up 6.49% in the past 24 hours, though technical indicators signal a bearish trend with 17 sell signals versus 2 buy signals. The stock faces resistance at $24 with support at $23. Recent news highlights China's economic policies and export controls, which may impact the underlying index exposure. Financial ratios remain unavailable for analysis.
The outlook is cautious due to bearish technicals and China-related macroeconomic risks. Opportunities exist if support holds and sentiment improves, but investors face volatility from regulatory developments and weak momentum. Risk management is essential given the conflicting signals between price action and technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
